Anti-VEGF and Retinal Dystrophies

Curr Drug Targets. 2020;21(12):1201-1207. doi: 10.2174/1389450121666200428103334.

Abstract

The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected by functional limitations. The study reports the effect of anti-VEGF treatment in several subforms of retinal dystrophies, critically discussing advantages and limitations.

Keywords: Choroidal neovascularization; anti-VEGF; best vitelliform macular dystrophy; macular edema retinitis pigmentosa; pattern dystrophy; stargardt disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / pathology
  • Humans
  • Macular Edema / drug therapy
  • Macular Edema / etiology
  • Retinal Dystrophies / complications
  • Retinal Dystrophies / drug therapy*
  • Retinal Dystrophies / pathology
  • Retinal Pigment Epithelium / drug effects
  • Retinitis Pigmentosa / complications
  • Retinitis Pigmentosa / drug therapy
  • Stargardt Disease / complications
  • Stargardt Disease / drug therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Vitelliform Macular Dystrophy / complications
  • Vitelliform Macular Dystrophy / drug therapy
  • Vitelliform Macular Dystrophy / pathology

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A